keyword
MENU ▼
Read by QxMD icon Read
search

DMARD

keyword
https://www.readbyqxmd.com/read/29676522/adalimumab-based-treatment-versus-dmards-for-venous-thrombosis-in-beh%C3%A3-et-syndrome-a-retrospective-study-of-70-patients-with-vascular-involvement
#1
Giacomo Emmi, Antonio Vitale, Elena Silvestri, Maria Boddi, Matteo Becatti, Claudia Fiorillo, Claudia Fabiani, Bruno Frediani, Lorenzo Emmi, Gerardo Di Scala, Matteo Goldoni, Alessandra Bettiol, Augusto Vaglio, Luca Cantarini, Domenico Prisco
OBJECTIVES: Since Behçet syndrome (BS) is the prototype of inflammation-induced thrombosis, immunosuppressants are recommended in place of anticoagulants. Here we assessed the clinical efficacy and the corticosteroid-sparing effect of adalimumab (ADA)-based treatment versus DMARDs in a large retrospective cohort of patients with BS-related venous thrombosis. METHODS: We retrospectively collected data from 70 BS patients treated with DMARDs or ADA-based regimens (ADA ± DMARDs) because of venous complications...
April 20, 2018: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/29669391/translational-biomarkers-and-ex-vivo-models-of-joint-tissues-as-a-tool-for-drug-development-in-rheumatoid-arthritis
#2
Cecilie F Kjelgaard-Petersen, Adam Platt, Martin Braddock, Martin A Jenkins, Kishwar Musa, Emma Graham, Thorbjørn Gantzel, Gillian Slynn, Michael E Weinblatt, Morten A Karsdal, Christian S Thudium, Anne-C Bay-Jensen
OBJECTIVE: Rheumatoid arthritis (RA) is a chronic, autoimmune and degenerative joint disease leading to disability, reduced life quality, and increased mortality. Although several synthetic and biological disease modifying anti-rheumatic drugs (DMARDs) are available, there is still a medical need for novel drugs controlling disease progression. As only 10% of RA drug candidates that enter phase I trials are eventually FDA registered, there is an immediate requirement for translational drug development tools to facilitate early drug development decision making...
April 18, 2018: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/29668129/-tuberculosis-in-the-era-of-anti-tnf-alpha-therapy-why-does-the-risk-still-exist
#3
John-Leonardo Torres-Castiblanco, Jorge Alberto Carrillo, Daniel Hincapié-Urrego, Adriana Rojas-Villarraga
Rheumatoid arthritis is an autoimmune systemic disease characterized mainly by inflammatory compromise of diarthrodial joints. Multiple drug therapies have been developed to control the activity of rheumatoid arthritis, among them, the first line of disease-modifying antirheumatic drugs (DMARD), and novel drug therapies such as the anti-TNF alpha therapy, with satisfactory clinical outcomes.Despite this positive fact, the use of this therapy implies the risk of producing negative effects due to its mechanism of action, which has been associated with multiple infections, especially tuberculosis, making it necessary to use screen tests before resorting to this kind of drugs...
March 15, 2018: Biomédica: Revista del Instituto Nacional de Salud
https://www.readbyqxmd.com/read/29667551/circulating-mir-10a-as-predictor-of-therapy-response-in-rheumatoid-arthritis-patients-treated-with-methotrexate
#4
Honghai Hong, Haihui Yang, Yong Xia
BACKGROUND: Anti-inflammatory drugs and DMARDs, especially methotrexate, have dramatically improved the outlook of RA patient. However, in some patients the treatment effect is still not satisfactory and needs to change therapeutic regimen in time. So, prediction of patient treatment effect timely is particularly important. METHODS: miRNAs are a large family of highly conserved noncoding genes and some of them become potential biomarker of disease diagnosis. In present study, we found circulating miR-10a was significantly decreased in RA patients compared to osteoarthritic patients and healthy people...
April 17, 2018: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/29667330/no-increased-risk-of-herpes-zoster-in-tnf-inhibitor-and-non-tnf-inhibitor-users-with-rheumatoid-arthritis-epidemiological-study-using-the-japanese-health-insurance-database
#5
Ryoko Sakai, Shoko Kasai, Fumio Hirano, Sayoko Harada, Mari Kihara, Waka Yokoyama, Michi Tsutsumino, Kenji Nagasaka, Ryuji Koike, Hisashi Yamanaka, Nobuyuki Miyasaka, Masayoshi Harigai
OBJECTIVE: It is controversial whether the use of biological disease-modifying antirheumatic drugs (DMARDs) increases the risk of herpes zoster (HZ). We aimed to evaluate the risks of HZ in tumor necrosis factor inhibitor (TNFI) and non-TNFI users with rheumatoid arthritis (RA) over 3 years in Japan. METHOD: Using the Japanese health insurance database, we assigned patients with at least one RA diagnostic code and one prescription for any DMARDs (RA cases) recorded between January 2005 and December 2013 to the RA group...
April 17, 2018: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/29667099/analysis-of-relapse-rates-and-risk-factors-of-tapering-or-stopping-pharmacologic-therapies-in-axial-spondyloarthritis-patients-with-sustained-remission
#6
Xiaochan Chen, Ting Zhang, Wenwen Wang, Jing Xue
The objectives of this study are to evaluate whether tapering or stopping strategies of pharmacologic therapies are efficacious for maintaining remission in patients with axial spondyloarthritis (axSPA) and to analyze the risk factors of disease relapse. Patients diagnosed as axSPA with ankylosing spondylitis disease activity score based on C reactive protein (ASDAS-CRP) ≤2.0 for at least 3 months were randomized into three groups: continuing non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs) (group 1), tapering NSAIDs and DMARDs by 50% (group 2), or discontinuing NSAIDs and DMARDs (group3) after 6 months of tapering...
April 18, 2018: Clinical Rheumatology
https://www.readbyqxmd.com/read/29656829/-uveitis-treated-with-biotherapy-and-or-dmard-analysis-from-the-french-pharmacovigilance-study-base
#7
L Cabane, S Baillif, B Baldin, V Breuil, L Euller-Ziegler, N Tieulié
PURPOSE: To report the characteristics of uveitis cases occurring while on biologic therapy or disease-modifying antirheumatic drugs (DMARDs) reported to the French national pharmacovigilance database. METHODS: All the uveitis cases occurring in patients with chronic rheumatologic diseases, chronic inflammatory intestinal diseases or connective tissue diseases, while treated with DMARDs and/or biologic therapies between 2000 and 2015 and reported to the French National Pharmacovigilance Database were collected...
April 13, 2018: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/29652655/effect-of-tumour-necrosis-factor-alpha-inhibitors-on-renal-function-in-patients-with-rheumatoid-arthritis-from-the-kobio-registry-from-2012-to-2016
#8
Seong-Kyu Kim, Jung-Yoon Choe, Sang Gyu Kwak, Jisuk Bae, Sung-Hoon Park, Hwajeong Lee
OBJECTIVES: The effect of biological disease-modifying anti-rheumatic drugs (bDMARDs) on renal function in patients with rheumatoid arthritis (RA) has not been well established. We assessed whether tumour necrosis factor (TNF) inhibitors could affect renal function in RA. METHODS: A total of 2110 patients with RA enrolled in the Korean College of Rheumatology Biologics (KOBIO) registry were analysed. All patients were taking bDMARDs or conventional synthetic DMARDs (csDMARDs)...
April 13, 2018: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29649840/-therapeutic-concepts-for-treatment-of-patients-with-non-infectious-uveitis-biologic-disease-modifying-antirheumatic-drugs
#9
Karoline Walscheid, Uwe Pleyer, Arnd Heiligenhaus
Biologic disease modifying antirheumatic drugs (bDMARDs) can be highly efficient in the treatment of various non-infectious uveitis entities. Currently, the TNF-α-inhibitor Adalimumab is the only in-label therapeutic option, whereas, all other bDMARDs need to be given as an off-label therapy. bDMARDs are indicated in diseases refractory to conventional synthetic DMARD therapy and/or systemic steroids, or in patients in whom treatment with those is not possible due to side effects. Therapeutic mechanisms currently employed are cytokine-specific (interferons, inhibition of TNF-α or of interleukin [IL]-1-, IL-6- or IL-17-signalling), inhibit T cell costimulation (CTLA-4 fusion protein), or act via depletion of B cells (anti-CD20)...
April 12, 2018: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/29624625/clinical-management-of-seronegative-and-seropositive-rheumatoid-arthritis-a-comparative-study
#10
Sang-Tae Choi, Kwang-Hoon Lee
Both rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (ACPA) are associated with poor radiologic outcomes in patients with rheumatoid arthritis (RA). In general, RA patients positive for RF or ACPA (SPRA) are considered to manifest an aggressive disease course compared with seronegative RA patients (SNRA). However, the relationship between seropositivity and measures of disease severity other than radiologic outcome is disputed. In this study, we sought to compare the clinical presentations and treatment outcomes of SNRA and SPRA patients...
2018: PloS One
https://www.readbyqxmd.com/read/29624580/estimating-the-response-and-economic-burden-of-rheumatoid-arthritis-patients-treated-with-biologic-disease-modifying-antirheumatic-drugs-in-taiwan-using-the-national-health-insurance-research-database-nhird
#11
Qiang Shi, Ko-Jen Li, Tamas Treuer, Bruce C M Wang, Carol L Gaich, Chien-Hsun Lee, Wen-Shuo Wu, Wesley Furnback, Chao-Hsiun Tang
BACKGROUND: Previous studies in Taiwan utilizing the Taiwan's National Health Insurance Database (NHIRD) have estimated the direct healthcare costs of RA patients, but they have not focused on patients on bDMARDs, or considered patients' response to therapy. OBJECTIVES: The objective of this study was to estimate the rate of inadequate response for patients newly treated with biologic disease-modifying antirheumatic drugs (bDMARDs) as well as their costs and resource use...
2018: PloS One
https://www.readbyqxmd.com/read/29623726/the-effect-of-biological-dmards-on-the-risk-of-congestive-heart-failure-in-rheumatoid-arthritis-a-systematic-review
#12
Milad Baniaamam, Walter J Paulus, Annelies B Blanken, Michael T Nurmohamed
A common cardiovascular manifestation in rheumatoid arthritis (RA) is congestive heart failure (CHF) in which inflammation is considered to play a pivotal role. Although anti-inflammatory therapy such as biological disease-modifying anti-rheumatic drugs (bDMARDs) have the potential of improving the cardiac function and reducing the risk of CHF, the published studies showed contrasting results. This review aims to systematically summarize and analyze literature regarding the effect of bDMARDs on the cardiac function and on the risk of CHF in RA...
April 6, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29618121/precision-medicine-using-different-biological-dmards-based-on-characteristic-phenotypes-of-peripheral-t-helper-cells-in-psoriatic-arthritis
#13
Ippei Miyagawa, Shingo Nakayamada, Kazuhisa Nakano, Satoshi Kubo, Shigeru Iwata, Yusuke Miyazaki, Maiko Yoshikawa, Hiroko Yoshinari, Yoshiya Tanaka
Objectives: We sought to investigate the selection of specific biological DMARDs (bDMARDs) based on characteristic lymphocyte phenotypes for treating PsA. Methods: Of 64 patients with PsA resistant to MTX, 26 underwent bDMARDs therapy selected according to phenotypic differences in peripheral helper T cells on 8-colour flow cytometry. The efficacies of this strategic treatment and the standard treatment administered to the other 38 patients were evaluated at 6 months...
April 2, 2018: Rheumatology
https://www.readbyqxmd.com/read/29614581/-2018-chinese-guideline-for-the-diagnosis-and-treatment-of-rheumatoid-arthritis
#14
(no author information available yet)
To develop a new evidence-based diagnosis, treatment guideline for rheumatoid arthritis (RA) in China.A multidisciplinary guideline development group was established. The grading of recommendations assessment, development and evaluation (GRADE) system was used to rate the quality of evidence and the strength of recommendations. Recommendations were derived from evidence body, the balance of benefits and harmsand patient's values and preferences.The guideline development group developed 10 recommendations for the diagnosis and treatment of RA...
April 1, 2018: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://www.readbyqxmd.com/read/29611446/costs-and-disease-activity-in-early-rheumatoid-arthritis-in-1996-2000-and-2006-2011-improved-outcome-and-shift-in-distribution-of-costs-a-two-year-follow-up
#15
M Husberg, L Bernfort, E Hallert
OBJECTIVE: To evaluate changes in healthcare utilization, costs, and disease activity from 1996 to 2011 for patients with early rheumatoid arthritis (RA). METHOD: Two cohorts of patients with early RA, included in 1996-1998 (T1) and 2006-2009 (T2), were followed regularly. Healthcare utilization, costs, and disease activity were compared between cohorts during 2 years after diagnosis. RESULTS: Disease activity was significantly improved in T2 vs T1...
April 3, 2018: Scandinavian Journal of Rheumatology
https://www.readbyqxmd.com/read/29610698/three-case-reports-of-rhupus-syndrome-an-overlap-syndrome-of-rheumatoid-arthritis-and-systemic-lupus-erythematosus
#16
Gul Devrimsel, Munevver Serdaroglu Beyazal
We present the clinical and serological characteristics of three patients with rhupus. The 3 patients with rhupus presented ACR criteria for SLE as well as for RA, ANA positive with a titer of 1/100 in all patients, and positive anti-DNA in 2 of the 3 patients, with the predominance of symmetrical polyarthritis. We found anti-CCP positivity and rheumatoid factor positivity and high titers in all patients, positive anti- anti-SSA in one patient, and positive anti- anti-Sm in one patient. Renal and liver function tests were normal in all patients...
2018: Case Reports in Rheumatology
https://www.readbyqxmd.com/read/29600949/clinical-remission-in-rheumatoid-arthritis-and-psoriatic-arthritis
#17
REVIEW
Ennio Lubrano, Federica Mesina, Roberto Caporali
It is currently recognised that remission can be an achievable target for several rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients by a treat-to-target approach. For RA different remission criteria have been proposed, depending on the disease activity scores used, on the importance given to the inclusion of patients' perspective into the definition of remission, and on their applicability in clinical practice, that generate highly different remission rates. Conversely, for PsA, remission is still insufficiently defined and represents a partially unmet need...
March 16, 2018: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29600942/serum-epstein-barr-virus-dna-detected-by-droplet-digital-pcr-correlates-with-disease-activity-in-patients-with-rheumatoid-arthritis
#18
Elina Kuusela, Vesa-Petteri Kouri, Juri Olkkonen, Riitta Koivuniemi, Leena Äyräväinen, Kristiina Rajamäki, Heikki Valleala, Dan Nordström, Marjatta Leirisalo-Repo, Mari Ainola, Kari K Eklund
OBJECTIVES: To study the prevalence of asymptomatic activation of Epstein-Barr virus (EBV) in patients with rheumatoid arthritis (RA) and to analyse the correlation of serum EBV DNA with the disease activity. METHODS: The level of EBV DNA was determined by droplet digital PCR assay from the serum of 46 DMARD naive early RA (ERA) and 22 chronic RA (CRA)-patients at study onset. Follow-up samples from 31 ERA and 16 CRA patients were obtained after starting or modifying the anti-rheumatic treatment...
March 20, 2018: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29600931/effects-of-biologic-disease-modifying-anti-rheumatic-drugs-on-the-radiographic-progression-of-rheumatoid-arthritis-a-systematic-literature-review
#19
REVIEW
Bernard Combe, Sadiq Lula, Caroline Boone, Patrick Durez
OBJECTIVES: To evaluate the effect of biologic disease-modifying anti-rheumatic drugs (bDMARDs) on radiographic progression in patients with rheumatoid arthritis (RA). METHODS: A systematic review of electronic databases and conference proceedings was conducted through January 2015, to identify randomised controlled trials (RCTs) and observational studies that assessed the impact of bDMARDs [± conventional synthetic DMARDs (csDMARDs), mainly methotrexate (MTX)], versus csDMARDs alone, on radiographic progression in patients with RA...
March 20, 2018: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29595700/starting-of-biological-disease-modifying-antirheumatic-drugs-may-be-postponed-in-rheumatoid-arthritis-patients-with-multimorbidity-single-center-real-life-results
#20
Berkan Armagan, Alper Sari, Abdulsamet Erden, Levent Kilic, Efe Cem Erdat, Saadettin Kilickap, Sedat Kiraz, Sule Apras Bilgen, Omer Karadag, Ali Akdogan, Ihsan Ertenli, Umut Kalyoncu
The objective of this study was to assess the frequency of comorbidities and multimorbidities in rheumatoid arthritis (RA) patients under biologic therapy and their effects on biological disease modifying antirheumatic drugs (DMARDs) choice, timing, and response.Hacettepe University Biologic Registry (HUR-BIO) is single center biological DMARD registry. Cardiovascular, infectious, cancer, and other comorbidities were recorded with face to face interviews. Multimorbidity is defined as >1 comorbidity. Disease duration, initial date of biological DMARDs, initial and overall biological DMARD choice were recorded...
March 2018: Medicine (Baltimore)
keyword
keyword
61414
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"